In a recent publication in Biomedicine & Pharmacotherapy, investigators evaluated the activity of a 7-amino-acid peptide, EB-203, using a zebrafish model of diabetic retinopathy (DR)-like vascular alterations.
Recent findings have shown that fatty acid synthase (FASN) is a promising therapeutic target in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) due to its involvement in de novo lipogenesis. Chinese researchers have recently published data on a FASN inhibitor, 84-B10, for the potential treatment of MASLD.
Newcelx Ltd. has entered into a collaborative research agreement with Eledon Pharmaceuticals Inc. with the aim of advancing its lead program, NCEL-101, for type 1 diabetes.
China Medical System Holdings Ltd. has received clinical trial approval from China’s National Medical Products Administration (NMPA) for CMS-D008 injection for overweight or obese individuals.
Pfizer Inc. has discovered substituted pyridine compounds acting as sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors and thus described as potentially useful for the treatment of diabetes, chronic kidney disease, nonalcoholic fatty liver disease (NAFLD; MASLD), phenylketonuria, metabolic syndrome, obesity, neurodevelopmental and autism-spectrum disorders, among others.
Sinopia Biosciences Inc. has entered into a target discovery collaboration with Ono Pharmaceutical Co. Ltd. focused on a group of rare metabolic disorders with significant unmet medical need.
Rongchang Pharmaceutical (Zibo) Co. Ltd. has synthesized nitrogen-containing fused ring compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of obesity and diabetes.
Alaunos Therapeutics Inc. has announced early data from two non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN-1003, the company’s lead small-molecule drug candidate for treating obesity and related conditions, such as metabolic dysfunction-associated steatotic liver disease (MASLD).
RSS
